Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03296696 · ClinicalTrials.gov registry record · Phase 1
Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03296696 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 30 participants.
The verdict
NCT03296696, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 monotherapy or in combination with AMG 404 in Subjects with Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII). This is a first in human (FIH), open-label, sequential-dose-escalation study in subjects with EGFRvIII-positive glioblastoma or malignant glioma. This study will enroll 2 groups of subjects according to disease stage, recurrent disease (Group 1) and maintenance treatment after SoC in newly diagnosed disease (Group 2).
Interventions
- DRUG AMG 404
- DRUG AMG 596
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2021-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03296696
The ClinicalTrials.gov registry entry for NCT03296696 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMG 404 is the first listed.
NCT03296696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03296696 about?
NCT03296696 is a clinical study titled "Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma". This is a Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 monotherapy or in combination with AMG 404 in Subjects with Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII). This is a first in hu...
What is the current status of trial NCT03296696?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-04-18. Estimated completion is 2021-08-28.
What interventions are being tested in trial NCT03296696?
The interventions under investigation include: AMG 404 (DRUG), AMG 596 (DRUG).
Who is sponsoring clinical trial NCT03296696?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.